Calmark Sweden AB logo

CALMA B BTU - Calmark Sweden AB News Story

SEK50 0.0  0.0%

Last Trade - 03/01/20

Sector
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 1782

BRIEF-Calmark Says Developing POC-Test To Help Assess Disease Severity For Patients With COVID-19 Patients

Thu 25th June, 2020 10:54pm
June 25 (Reuters) - Calmark Sweden AB  CALMAb.TE :
    * CALMARK IS DEVELOPING A POC-TEST TO HELP ASSESS DISEASE SEVERITY FOR PATIENTS WITH
COVID-19
PATIENTS
    * CALMARK SWEDEN - TO PRIORITIZE DEVELOPMENT OF A DIAGNOSTIC POINT-OF-CARE TEST FOR LACTATE
DEHYDROGENASE BIOMARKER AIMED AT ADULT PATIENTS WITH COVID-19
    * CALMARK SWEDEN - LACTATE DEHYDROGENASE BIOMARKER HAS BEEN SHOWN IN SEVERAL STUDIES TO BE
HELPFUL
IN DETERMINING PROGNOSIS IN PATIENTS WITH COVID-19

Source text for Eikon:  ID:nWkrVdpWp 
Further company coverage:  CALMAb.TE 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.